

BMJ Open

Assessing bias in osteoarthritis trials included in Cochrane reviews: Protocol for a meta-epidemiological study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005491
Article Type:	Protocol
Date Submitted by the Author:	16-Apr-2014
Complete List of Authors:	Hansen, Julie; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg Juhl, Carsten; SEARCH research group, Research Unit of Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark, BOUSTRON, Isabelle; INSERM, APHP, University Paris Descartes Tugwell, Peter; University of Ottawa, medicine Ghogomu, Elizabeth; Cochrane Musculoskeletal Group, University of Ottawa, Pardo Pardo, Jordi; Centre for Global Health, University of Ottawa, Rader, Tamara; Cochrane Musculoskeletal Group, University of Ottawa, Wells, George ; Ottawa Hospital Research Institute, Mayhew, Alain; Cochrane Bias Methods Group, Ottawa, Canada, Maxwell, Lara; Cochrane Bias Methods Group, Ottawa, Canada, Lund, Hans; University of Southern Denmark, 3. Institute of Sports Science and Clinical Biomechanics Christensen, Robin; Copenhagen University Hospital, Frederiksberg, The Parker Institute: MSU
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology, Research methods, Rheumatology
Keywords:	osteoarthritis, meta-analysis, meta-epidemiology, risk of bias

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Assessing bias in osteoarthritis trials included in Cochrane reviews:**

2 **Protocol for a meta-epidemiological study**

3
4 Julie B. Hansen,^{1,2} Carsten B. Juhl,² Isabelle Boutron,^{3,4} Peter Tugwell,⁵ Elizabeth Ghogomu,⁶ Jordi
5 Pardo Pardo,⁷ Tamara Rader,⁶ George A. Wells,⁸ Alain Mayhew,^{4,9} Lara Maxwell,⁶ Hans Lund,²
6 Robin Christensen,^{1,2} and The Editorial Board of the Cochrane Musculoskeletal Group.

7
8 1: Musculoskeletal Statistics Unit, The Parker Institute, Dept. Rheum., Copenhagen University Hospital, Bispebjerg and
9 Frederiksberg, Copenhagen, Denmark.

10 2: SEARCH research group, Research Unit of Musculoskeletal Function and Physiotherapy, Institute of Sports Science
11 and Clinical Biomechanics, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

12 3: NSERM, University Paris Descartes, Paris, France

13 4: Cochrane Bias Methods Group, Ottawa, Canada

14 5: Ottawa Hospital Research Institute, Joint Coordinating Editor CMSG

15 6: Cochrane Musculoskeletal Group, University of Ottawa

16 7: Centre for Global Health, University of Ottawa

17 8: Epidemiology and Community Medicine, University of Ottawa

18 9: Ottawa Hospital Research Institute, Centre for Practice-Changing Research, Ottawa, Canada

19 20 **Correspondence to:**

21 Robin Christensen, BSc, MSc, PhD; senior biostatistician

22 Head of Musculoskeletal Statistics Unit,

23 The Parker Institute, Department of Rheumatology,

24 Copenhagen University Hospital, Bispebjerg and Frederiksberg,

25 Nordre Fasanvej 57

26 DK-2000 Copenhagen F

27 Denmark

28 Phone: (+45) 3816 4165

29 Fax: (+45) 3816 4159

30 E-mail: Robin.Christensen@frh.regionh.dk

31
32 **Keywords:** osteoarthritis, meta-analysis, meta-epidemiology, risk of bias

33 **Word count** (excl. title page, abstract and references): 2286

Author	E-mail address
JBH	juliebolvig@gmail.com
CBJ	cjuhl@health.sdu.dk
IB	isabelle.boutron@htd.aphp.fr
PT	Tugwell.BB@uOttawa.ca
EG	cmsg@uottawa.ca
JPP	jpardo@uottawa.ca
TR	trader@uottawa.ca
GAW	gawells@ottawaheart.ca
AM	almayhew@ohri.ca
LM	lmaxwell@uottawa.ca
HL	hlund@health.sdu.dk
RC	Robin.Christensen@frh.regionh.dk

1

2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **ABSTRACT**

2 **Introduction**

3 The validity of systematic reviews and meta-analysis depends on methodological quality and
4 unbiased dissemination of trials. Our objective is to evaluate the association of estimates of
5 treatment effects with different bias-related study characteristics in meta-analyses of
6 interventions used for treating pain in osteoarthritis (OA). From the findings, we hope to
7 consolidate guidance on interpreting OA trials in systematic reviews based on empirical evidence
8 from Cochrane reviews.

10 **Methods and analysis**

11 Only systematic reviews that compare experimental interventions with sham, placebo, or no
12 intervention control will be considered eligible. Bias will be assessed with the risk of bias tool,
13 used according to the Cochrane Collaboration's recommendations. Furthermore, single vs.
14 multicentre trial status, trial size, and funding will be assessed. The primary outcome (pain) will be
15 abstracted from the first appearing forest plot for overall pain in the Cochrane review.

16 Treatment effect sizes (ESs) will be expressed as standardised mean differences
17 (SMDs), where the difference in mean values available from the forest plots is divided by the
18 pooled standard deviation (SD). To empirically assess the risk of bias in treatment benefits, we will
19 perform stratified analyses of the trials from the included meta-analyses and assess the
20 interaction between trial characteristics and treatment effect. A relevant study-level covariate is
21 defined as one that decreases the between-study variance (τ^2 , estimated as Tau-squared [T^2]) as a
22 consequence of inclusion in the mixed effects statistical model.

24 **Ethics and dissemination**

25 Meta-analyses and randomised controlled trials provide the most reliable basis for treatment of
26 patients with OA, but the actual impact of bias is unclear. This study will systematically examine
27 the methodological quality in OA Cochrane reviews and explore the effect estimates behind
28 possible bias. Because our study does not collect primary data, no formal ethical assessment and
29 informed consent are required.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3

Protocol registration PROSPERO (CRD42013006924)

For peer review only

1 INTRODUCTION

2 The Cochrane Musculoskeletal Group (CMSG) is one of the 53 existing review groups in the
3 Cochrane Collaboration, which aims to prepare, maintain, and disseminate high-quality systematic
4 reviews for musculoskeletal diseases including osteoarthritis; and help health care providers,
5 patients and carers to make well-informed decisions on prevention, treatment and management
6 of musculoskeletal conditions^{1,2} (<http://musculoskeletal.cochrane.org/more-about-us> 29. Aug
7 2013). The Cochrane Collaboration makes a considerable contribution to reduce bias in scientific
8 interpretation of research.³⁻⁵ Systematic reviews founded on randomised trials provide the most
9 reliable evidence about the effects of healthcare interventions.⁶ Unfortunately, inadequate
10 methodology may distort the outcomes from systematic reviews and meta-analyses⁷ and produce
11 misleading results.⁸

12 Description of the problem or issue

13 Bias in trials can lead to underestimation or overestimation of the true intervention effect.^{9,10}
14 Regardless of the *tools* used to assess risk of bias, the *methods* for assessing and summarising
15 potential bias and incorporating bias assessments into meta-analyses vary greatly.^{3,4} Bias
16 associated with particular characteristics of studies may be examined using meta-epidemiology,
17 which analyses a cluster of meta-analyses where the influence of the trial characteristics—such as
18 judgements on risk of bias on treatment effects estimates—is explored.⁸ By using meta-
19 epidemiologic studies, it is possible to examine the association of specific trial characteristics in a
20 collection of meta-analyses and their included trials.^{11,12}

21
22 Most meta-epidemiologic studies focus on allocation concealment and blinding and
23 their influence on treatment effects of dichotomous outcomes,^{12,13} but this study will focus on
24 other characteristics as well: attrition bias, reporting bias, the issue of single centre vs. multicentre
25 trials, and funding. Further, this study will focus on pain—a continuous patient reported outcome
26 (PRO: Non-drug intervention trials researching treatment in osteoarthritis are difficult to blind; the
27 patients might know whether they are receiving the intervention or control, which could affect
28 their (self-reported) pain scores.

Description of the methods being investigated

Much research has been conducted to understand bias in trials and how it may influence the results of systematic reviews.⁵ In 2001, the Cochrane Bias Methods Group was established to investigate how bias influences primary studies. Through its acknowledged work, the group developed the Cochrane risk of bias tool in 2008, based on the methodological contributions of meta-epidemiological studies. This tool has since been updated is a mandatory component of Cochrane reviews.⁴ There remain additional possible contributors to bias which are not currently standard components for the Cochrane risk of Bias tool.

At the Cochrane Methods Symposium in Quebec City, Canada, October 2013, L. Bero and J. Sterne –among others –contributed in a debate on whether or not to include funding as a standard domain in the Cochrane risk of bias tool, or if the bias related to source of funding could be captured as part of various “reporting biases,” as eligible studies tend to remain unpublished for reasons related to their “negative” results.^{14,15}

Studies have suggested that the number of study sites might have an influence on effect size.¹⁶ Single-centre trials tend to include more homogeneous populations within the (highly selected) study eligibility criteria, and they are more likely than multicentre trials to perform well in experienced teams of providers with expertise in the specific technical or other aspects of an intervention.¹⁶ However, single-centre trials risk overestimating effect sizes.¹⁶

Trial size also is known for being inversely associated with bigger effect estimates. This phenomenon could be a reflection of smaller trials' being prone to reporting bias: studies with statistically significant results tend to be published more frequently than those with non-significant results.¹⁷ However, the larger the trial, the greater the probability that results are published.¹⁸ Furthermore, smaller trials might tend to be more susceptible to overall bias assessed by the Cochrane risk-of-bias tool.¹⁸

Why this review is needed

Bias domains from the Cochrane risk of bias tool (selection bias, performance bias, detection bias, attrition bias, and reporting bias), centre status, trials size, and source of funding risk positively influencing an experimental treatment if they are found inadequate or unclear.^{11,18,19} A meta-epidemiological study assessing binary outcomes showed that odds ratios (ORs) from trials with

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

unclear or inadequate concealment were on average 30% lower (i.e., more beneficial to the intervention) than ORs from trials with adequate methodology (combined ratio of ORs 0.70, 95% CI 0.62 to 0.80).⁷ Results for binary outcomes may not be extrapolated to trials assessing continuous outcomes because such trials usually differ in medical condition, risk of bias, sample size, and statistical analysis.²⁰

In spite of this knowledge, systematic reviews and meta-analyses still provide summary data to policymakers, health care professionals, patients and their relatives to make decisions about the patients' treatment and well-being. It is interesting to explore whether these systematic reviews and meta-analyses provide the true effect estimates, and if all these groups are making decisions on the basis of spurious (biased) effect estimates. The validity of systematic reviews and meta-analysis is depending on methodological quality and unbiased dissemination of trials.²¹The association between methodological components and the overestimated treatment effects will be determined in this meta-epidemiological study, which will enable us to provide guidance on how to interpret OA trials in systematic reviews based on empirical evidence from Cochrane reviews.

Objectives

Our objective is to evaluate the association between estimates of treatment effects with different bias-related study characteristics^{11,12,16,20,22,23} in meta-analyses of interventions used for treating OA pain.

METHODS

Protocol and registration

Our protocol is registered on PROSPERO (CRD42013006924); our protocol manuscript conforms to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting systematic reviews and meta-analyses.²⁴

1 Eligibility criteria

2 Only systematic reviews of randomised or controlled trials available will be used in this analysis.
 3 Only systematic reviews that compare experimental interventions with sham, placebo, or no
 4 intervention control in patients with OA and which use a patient-reported pain measure as an
 5 outcome will be considered eligible. Moreover, only trials where patients in both the intervention
 6 and the control group receive the same treatment except from an add-on in the intervention
 7 group will be eligible for inclusion. Reviews will be excluded if no relevance is found when reading
 8 the title and abstract. Further exclusion will be made if the review did not report a meta-analysis
 9 on pain—preferably a meta-analysis showing overall pain, including at least two trials. Two
 10 reviewers will independently evaluate the reports for eligibility, and any disagreements will be
 11 resolved by discussion or by involvement of a third reviewer. Data will be eligible from the trials,
 12 which are included in eligible reviews and meta-analyses.

14 Search for meta-analyses and inclusion of trials

15 We will search the Cochrane Database of Systematic Reviews via the Cochrane Library for
 16 osteoarthritis reviews using a combination of MeSH terms and natural language vocabulary (see
 17 **Table 1**). The latest update of the Cochrane review will be used. Eligible trials will be identified
 18 from the reference lists of the published Cochrane reviews.

20 **Table 1.** Search Strategy, Cochrane Library via Wiley Issue 4, 2014

Search	Terms
#1	MeSH descriptor: [Osteoarthritis] explode all trees
#2	osteoarthr*:ti,ab
#3	degenerative near/2 arthritis:ti,ab
#4	(#1 or #2 or #3)

22 Risk of bias in individual studies

23 *Cochrane risk of bias tool:*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 The risk of bias within each full-text trial will be assessed using the domains of the risk of bias tool
2 as recommended by the Cochrane Collaboration,⁴ which comprise methods for sequence
3 generation and maintaining allocation concealment, blinding, and management of incomplete
4 outcome data. Each domain will be rated as adequate, inadequate, or unclear risk of bias (see
5 **Table 2**).

7 ***Other risk of bias items:***

8 In the course of meta-epidemiologic studies, other sources, such as significant discrepancies
9 between single vs. multicentre trials,¹⁶ small vs. large trials,¹⁸ and source of funding²⁵ arises as
10 possible risk of bias domains (see Table 2).

12 **Data collection process and data items**

13 We will use a systematic, standardised data extraction approach to gather information from all
14 eligible OA studies. The primary outcome (pain) will be abstracted from overall pain reported in
15 the Cochrane review's first pain measure forest plot. Outcome will be collected at the time point
16 closest to 12 weeks' follow-up. Two reviewers will independently extract data from the trials.

18 ***"Systematic review-level" data extraction***

19 At the level of the systematic review, we will extract data on review ID, author, year of publication,
20 and accumulated trial size combined in the meta-analysis (i.e., N_{Total} , N_I , and N_C). Type of
21 intervention will be categorised according to the "suggested sequential, pyramid approach to
22 management of OA" by Dieppe & Lohmander²⁷ and the *Osteoarthritis Research Society*
23 *International* (OARSI) recommendations²⁸ (see, **Table 3**, OA intervention categories).

25 ***"Trial-level" data extraction***

26 At the trial level, we will assign studies a trial ID and extract information on author name, year of
27 publication, type of pain measure, type of intervention, and type of OA condition. From the forest
28 plot available in the included review, we will extract the following study-level covariates: mean
29 values (m_I and m_C), standard deviations (sd_I and sd_C) and size of the trials.

1 **Table 2.** Risk of bias assessment table

Bias domain	Bias item	Review authors judgment (adequate, inadequate, or unclear)
Selection Bias	Sequence generation	Sequence generation will be regarded as adequate if a random approach in the sequence generation process –referred to as a random number table, a random computer-generated number, coin tossing, drawing of lots, shuffling cards, or throwing dice—is described. Date of inclusion or admission, or record number of clinic/hospital will be considered inadequate. Deficient information about the process will be considered as unclear.
	Allocation concealment	Allocation concealment will be regarded as adequate if sequentially numbered, sealed, opaque envelopes, numbered or coded medical containers, or a centralised randomisation is applied. If it is possible to predict the assignment, allocation concealment will be regarded as inadequate. Therefore, date of birth, application of an open random allocation schedule, or any other explicitly unconcealed procedure will be regarded as inadequate. The allocation concealment will be regarded as unclear if the method of concealment is not available.
Performance Bias	Blinding of participants	Blinding of patients will be regarded as adequate if intervention and control treatment are described as indistinguishable, or if it is unlikely that the blinding could have been broken for both patients and data collectors. Deficient information about the blinding process will be considered as unclear.
Detection bias	Blinding of key study personnel	Blinding of key study personnel will be regarded as adequate if intervention and control treatment are described as indistinguishable, or if it is unlikely that the blinding could have been broken for data collectors and key study personnel. Deficient information about the blinding process will be considered as unclear.
Attrition bias	Incomplete outcome data	Data will be regarded as adequate (complete) if there are no missing outcome data or if the missing data constitute less than 10% of total number of participants at baseline and if no differences in reasons for dropout were observed between the groups. Further, outcome data will be considered adequate if missing data have been imputed using appropriate statistical methods like intention to treat (ITT). Deficient information about the blinding process will be regarded as unclear.
Other bias	Centre status	A trial will be considered a multicentre trial if more than one centre is involved. In case of missing information, the trial will be classified as multicentre if it reports both several ethics committees and different affiliations of authors. If the report stated both a single ethics committee and a single author affiliation, the trial will be classified as a single centre. Information about single- and multicentre trials will be extracted from the text, statements, author's affiliations, and acknowledgement in every included trial.
	Trial size	To judge whether a trial is small or large, we will use a threshold of 128 participants. If the total number of randomised participants is less than 128 patients, the study will be regarded as a small trial; trials with ≥ 128 participants will be referred to as large trials. The threshold of 64 participants in each group corresponds to a reasonable power (80%) to detect a standardised mean difference (SMD) ≥ 0.5 . ²⁶
	Funding	Trials will be specified either as being funded by for-profit funding or non-profit funding. Non-profit funding includes money received from both non-profit organizations (e.g., Internal hospital funding and governmental funding) and not funded trials. For-profit organizations will be defined as companies that might acquire financial gain or loss depending on the outcome of the trial. Further, trials with a mix of for-profit and non-profit or if the funding is not reported, will be considered as for-profit funded. Funding is defined as including provision of manpower (authorship, statistical analysis, or other assistance), study materials (drug, placebo, assay kits, or similar materials), or grants. ²⁵ Sources of funding will be extracted from the text, statements of sources of support, authors' affiliations, acknowledgments, and trial registration, if available.

2

3 The size of the study will be handled in two ways: (i) trial size according to the meta-analysis (i.e.,
4 forest plot, n_i and n_c), and (ii) trial size according to the original (ITT) population according to the
5 trial report (N_i and N_c). Further, we will assess the following characteristics from the trials:

1 attrition rate during the trial (a_{Total} , a_I , and a_C), and trial duration (weeks). Further, we will extract
 2 information on the comparator groups applied in each trial, whether placebo/sham or waiting-
 3 list/nothing.

4
 5 **Table 3** Intervention categories

Non-pharmacological modalities of treatment (NP)	Pharmacological modalities of treatment (P)	Surgical modalities of treatment (S)
a) General information and advice (education, regular contact with caregiver, lifestyle alterations, etc.) b) Exercise and therapy (physical and occupational therapy, aerobic, muscle strength, ROM training, water exercise, etc.) c) Weight loss d) Walking and other aids (e.g., canes, wheeled walkers, assistive technology such as orthoses, braces, insoles) e) Thermal modalities, transcutaneous electrical nerve stimulation (TENS), acupuncture, etc.	f) Paracetamol (acetaminophen) g) NSAIDs (topical or oral) h) Intra-articular injections with corticosteroids or hyaluronate i) Nutraceuticals (e.g., glucosamine, chondroitin sulphate, rosehip powder) j) Opioids (weak: tramadol, codeine etc.; stronger: morphine, etc.)	k) Surgery (joint preserving; osteotomy and resurfacing and partial or total joint replacement)

6
 7 **Data synthesis**

8 Treatment effect sizes (ES) will be expressed as SMD by dividing the difference in mean values
 9 available from the forest plots by the SD. Negative effect sizes will indicate a beneficial effect of
 10 the experimental intervention (i.e., pain reduction). We will register whether the data are

1 expressed as values from follow-up, change from baseline, or a mix, as studies have shown that
2 there is no relevant difference between follow-up and change data SMDs in meta-analysis.²⁹

3 **Statistical analysis**

4 To empirically assess the risk of bias in the treatment effects in reviews, we will perform stratified
5 analyses across trials according to all the different extracted trial characteristics and derive P-
6 values for interaction between trial characteristics and treatment effect. Within each systematic
7 review, the ES for trial effects according to the different risk of bias assessments will be estimated
8 by using a random effect meta-analysis model. The differences between the pooled estimates will
9 be derived and combined using random effect meta-analysis fully allowing for heterogeneity, to
10 measure the variability in bias estimates, expressed in τ^2 . A relevant study-level covariate is
11 defined as one that decreases the between-study variance (τ^2 , estimated as Tau-squared [T^2]) as a
12 consequence of inclusion in the mixed-effects statistical model. All the statistical meta-regression
13 analyses will be based on REstricted Maximum Likelihood (REML) (i.e., random-effects) models;³⁰
14 models will be developed and analysed using SAS software (version 9.2, by SAS Institute Inc., Cary,
15 NC, USA).

17 **ETHICS AND DISSEMINATION**

18 We believe that the findings of this meta-epidemiological study will have important implications
19 for future research strategies and implementation of study conclusions. Meta-analyses and
20 randomised controlled trials provide the most reliable basis for treating patients with OA.
21 However, even though the influence of bias items is well known and described, authors tend to
22 forget that biased trials included in systematic reviews will cause meta-analyses to be biased.³¹

23 Therefore, it is essential that those who conduct systematic reviews be familiar with
24 the potential biases within primary studies and how such biases could influence review results and
25 the ensuing conclusions. Still, many Cochrane review authors are reluctant or fail to incorporate
26 the risk of bias assessment in their analysis and conclusions,³² compromising the trustworthiness
27 of results from meta-analysis derived from these reviews. Although the Cochrane Collaboration
28 has changed the way it assesses bias in included trials⁵ owing to Ken Schulz's work on bias

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

assessment,²² the Cochrane risk of bias tool in 2008,³³ AMSTAR (Assessing the methodological quality of systematic reviews checklist),³⁴ and the grading of recommendations assessment, development and evaluation (GRADE) approach,³⁵ meta-analyses might still overestimate the effect estimates from biased studies.

After two decades of assessing risk of bias, it is clearly time we examine whether the tool for assessing risk of bias is complete³² What items should be added or removed? Which items have the greatest impact on estimates of effect? This study will examine the evidence in CMSG reviews using patient reported outcomes from OA trials as an example and explore the true implications on effect estimates behind the possible shades of bias. As this study collects no primary data, no additional formal ethical assessment and informed consent are required.

Acknowledgement

We thank the Parker Institute, Frederiksberg Hospital, and The Oak Foundation for creating the possibility and right settings for this research. Additionally, we thank the Cochrane Musculoskeletal Group Editorial based at The University of Ottawa, Centre for Global Health.

Contributors

JBH, RC, CBJ, PT, and HL conceived and designed the study, and JBH, RC, and CBJ contributed to the development of the protocol. All of the authors (JBH, CBJ, IB, PT, EG, JPP, TR, GAW, AM, LM, HL, and RC) assisted in the final protocol and agreed to its final approval before submission.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. This research was funded by The Oak Foundation, which had no role in study design, data collection, data synthesis, data interpretation, writing the report, or the decision to submit the manuscript for publication.

Competing interests

This study had no financial competing interests. The Parker Institute's Musculoskeletal Statistics Unit is grateful for the financial support received from public and private foundations, companies,

1 and private individuals over the years. The Parker Institute is supported by a core grant from the
2 Oak Foundation; The Oak Foundation is a group of philanthropic organizations that, since its
3 establishment in 1983, has given grants to not-for-profit organisations around the world.

4
5 All the authors are involved with different health care initiatives and research (including Cochrane,
6 OMERACT, and the GRADE Working Group) that could benefit from wide uptake of this
7 publication.

8 9 REFERENCES

- 10
11 (1) Ghogomu EA, Maxwell LJ, Buchbinder R, Rader T, Pardo PJ, Johnston RV et al. Updated
12 method guidelines for cochrane musculoskeletal group systematic reviews and
13 metaanalyses. *J Rheumatol* 2014; 41(2):194-205.
- 14 (2) Maxwell L, Santesso N, Tugwell PS, Wells GA, Judd M, Buchbinder R. Method guidelines for
15 Cochrane Musculoskeletal Group systematic reviews. *J Rheumatol* 2006; 33(11):2304-2311.
- 16 (3) Lundh A, Gotzsche PC. Recommendations by Cochrane Review Groups for assessment of
17 the risk of bias in studies. *BMC Med Res Methodol* 2008; 8:22.
- 18 (4) Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al. The Cochrane
19 Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; 343:d5928.
- 20 (5) Turner L, Boutron I, Hrobjartsson A, Altman DG, Moher D. The evolution of assessing bias in
21 Cochrane systematic reviews of interventions: celebrating methodological contributions of
22 the Cochrane Collaboration. *Syst Rev* 2013; 2:79.
- 23 (6) Mulrow CD. The medical review article: state of the science. *Ann Intern Med* 1987;
24 106(3):485-488.
- 25 (7) Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of
26 controlled clinical trials. *BMJ* 2001; 323(7303):42-46.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- (8) Sterne JA, Juni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research. *Stat Med* 2002; 21(11):1513-1524.
- (9) gado-Rodriguez M, Llorca J. Bias. *J Epidemiol Community Health* 2004; 58(8):635-641.
- (10) Gluud LL. Bias in clinical intervention research. *Am J Epidemiol* 2006; 163(6):493-501.
- (11) Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ* 2008; 336(7644):601-605.
- (12) Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. *Health Technol Assess* 2012; 16(35):1-82.
- (13) Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. *Health Technol Assess* 2012; 16(35):1-82.
- (14) Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item. *Cochrane Database of Systematic Reviews* 2013.
- (15) Sterne JAC. Why the Cochrane risk of bias tool should not include funding source as a standard item [editorial]. *Cochrane Database of Systematic Reviews* 2013.
- (16) Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P. Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. *Ann Intern Med* 2011; 155(1):39-51.

- 1
2
3
4 1 (17) Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E et al. Systematic review of the
5 empirical evidence of study publication bias and outcome reporting bias. *PLoS One* 2008;
6 2 3(8):e3081.
7 3
8
9
10 4 (18) Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment
11 effect estimates: meta-epidemiological study. *BMJ* 2013; 346:f2304.
12 5
13
14 6 (19) Lundh A, Sismondo S, Lexchin J, Busuioac OA, Bero L. Industry sponsorship and research
15 outcome. *Cochrane Database Syst Rev* 2012; 12:MR000033.
16 7
17
18 8 (20) Bafeta A, Dechartres A, Trinquart L, Yavchitz A, Boutron I, Ravaud P. Impact of single centre
19 status on estimates of intervention effects in trials with continuous outcomes: meta-
20 epidemiological study. *BMJ* 2012; 344:e813.
21 9
22
23 10 (21) Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of
24 therapy. I: Medical. *Stat Med* 1989; 8(4):441-454.
25 11
26
27 12 (22) Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of
28 methodological quality associated with estimates of treatment effects in controlled trials.
29 *JAMA* 1995; 273(5):408-412.
30 13
31
32 14 (23) Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies
33 between large and small randomized trials in meta-analyses. *Ann Intern Med* 2001;
34 15 135(11):982-989.
35
36 16 (24) Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al. The PRISMA
37 statement for reporting systematic reviews and meta-analyses of studies that evaluate
38 healthcare interventions: explanation and elaboration. *BMJ* 2009; 339:b2700.
39 17
40 18
41
42 19 (25) Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in
43 randomized drug trials: a reflection of treatment effect or adverse events? *JAMA* 2003;
44 20 290(7):921-928.
45 21
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 (26) Norman GR, Sloan JA, Wyrwich KW. The truly remarkable universality of half a standard
2 deviation: confirmation through another look. *Expert Rev Pharmacoecon Outcomes Res*
3 2004; 4(5):581-585.
- 4 (27) Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. *Lancet*
5 2005; 365(9463):965-973.
- 6 (28) Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N et al. OARSI
7 recommendations for the management of hip and knee osteoarthritis, Part II: OARSI
8 evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage* 2008; 16(2):137-162.
- 9 (29) da Costa BR, Nuesch E, Rutjes AW, Johnston BC, Reichenbach S, Trelle S et al. Combining
10 follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-
11 epidemiological study. *J Clin Epidemiol* 2013; 66(8):847-855.
- 12 (30) Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and
13 interpreted? *Stat Med* 2002; 21(11):1559-1573.
- 14 (31) Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P et al. GRADE guidelines: 4.
15 Rating the quality of evidence--study limitations (risk of bias). *J Clin Epidemiol* 2011;
16 64(4):407-415.
- 17 (32) Hrobjartsson A, Boutron I, Turner L, Altman DG, Moher D. Assessing risk of bias in
18 randomised clinical trials included in Cochrane Reviews: the why is easy, the how is a
19 challenge. *Cochrane Database Syst Rev* 2013; 4:ED000058.
- 20 (33) Higgins JPT ADSJe. Chapter 8: Assessing risk of bias in included studies. *Cochrane Handbook*
21 *for Systematic Reviews of Interventions*. Cochrane Handbook for Systematic Reviews of
22 Interventions ed. 2011.
- 23 (34) Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C et al. Development of
24 AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.
25 *BMC Med Res Methodol* 2007; 7:10.

- 1
2
3
4 1 (35) Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y,onso-Coello P et al. GRADE: an
5
6 2 emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*
7
8 3 2008; 336(7650):924-926.
9
10 4
11 5
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3,4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5,6,7
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	7
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	7
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	8
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	8
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	9,10,11
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	9,10,11
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	9,10
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	11
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis).	11,12



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	10
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	23
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	No results – this is a protocol
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	No summary of evidence, limitations and conclusion – this is a protocol
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	13

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only

BMJ Open

Assessing bias in osteoarthritis trials included in Cochrane reviews: Protocol for a meta-epidemiological study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005491.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Jun-2014
Complete List of Authors:	Hansen, Julie; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg Juhl, Carsten; SEARCH research group, Research Unit of Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark, BOUFRON, Isabelle; INSERM, APHP, University Paris Descartes Tugwell, Peter; University of Ottawa, medicine Ghogomu, Elizabeth; Cochrane Musculoskeletal Group, University of Ottawa, Pardo Pardo, Jordi; Centre for Global Health, University of Ottawa, Rader, Tamara; Cochrane Musculoskeletal Group, University of Ottawa, Wells, George ; Ottawa Hospital Research Institute, Mayhew, Alain; Cochrane Bias Methods Group, Ottawa, Canada, Maxwell, Lara; Cochrane Bias Methods Group, Ottawa, Canada, Lund, Hans; University of Southern Denmark, 3. Institute of Sports Science and Clinical Biomechanics Christensen, Robin; Copenhagen University Hospital, Frederiksberg, The Parker Institute: MSU
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology, Research methods, Rheumatology
Keywords:	osteoarthritis, meta-analysis, meta-epidemiology, risk of bias

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Assessing bias in osteoarthritis trials included in Cochrane reviews:**

2 **Protocol for a meta-epidemiological study**

3
4 Julie B. Hansen,^{1,2} Carsten B. Juhl,² Isabelle Boutron,^{3,4} Peter Tugwell,⁵ Elizabeth Ghogomu,⁶ Jordi
5 Pardo Pardo,⁷ Tamara Rader,⁶ George A. Wells,⁸ Alain Mayhew,^{4,9} Lara Maxwell,⁶ Hans Lund,²
6 Robin Christensen,^{1,2} and The Editorial Board of the Cochrane Musculoskeletal Group.

7
8 1: Musculoskeletal Statistics Unit, The Parker Institute, Dept. Rheum., Copenhagen University Hospital, Bispebjerg and
9 Frederiksberg, Copenhagen, Denmark.

10 2: SEARCH research group, Research Unit of Musculoskeletal Function and Physiotherapy, Institute of Sports Science
11 and Clinical Biomechanics, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

12 3: NSERM, University Paris Descartes, Paris, France

13 4: Cochrane Bias Methods Group, Ottawa, Canada

14 5: Ottawa Hospital Research Institute, Joint Coordinating Editor CMSG

15 6: Cochrane Musculoskeletal Group, University of Ottawa

16 7: Centre for Global Health, University of Ottawa

17 8: Epidemiology and Community Medicine, University of Ottawa

18 9: Ottawa Hospital Research Institute, Centre for Practice-Changing Research, Ottawa, Canada

19 20 **Correspondence to:**

21 Robin Christensen, BSc, MSc, PhD; senior biostatistician

22 Head of Musculoskeletal Statistics Unit,

23 The Parker Institute, Department of Rheumatology,

24 Copenhagen University Hospital, Bispebjerg and Frederiksberg,

25 Nordre Fasanvej 57

26 DK-2000 Copenhagen F

27 Denmark

28 Phone: (+45) 3816 4165

29 Fax: (+45) 3816 4159

30 E-mail: Robin.Christensen@frh.regionh.dk

31
32 **Keywords:** osteoarthritis, meta-analysis, meta-epidemiology, risk of bias

33 **Word count** (excl. title page, abstract and references): 2286

34

Author	E-mail address
JBH	juliebolvig@gmail.com
CBJ	cjuhl@health.sdu.dk
IB	isabelle.boutron@htd.aphp.fr
PT	Tugwell.BB@uOttawa.ca
EG	cmsg@uottawa.ca
JPP	jpardo@uottawa.ca
TR	trader@uottawa.ca
GAW	gawells@ottawaheart.ca
AM	almayhew@ohri.ca
LM	lmaxwell@uottawa.ca
HL	hlund@health.sdu.dk
RC	Robin.Christensen@frh.regionh.dk

1

2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **ABSTRACT**

2 **Introduction**

3 The validity of systematic reviews and meta-analysis depends on methodological quality and
4 unbiased dissemination of trials. Our objective is to evaluate the association of estimates of
5 treatment effects with different bias-related study characteristics in meta-analyses of
6 interventions used for treating pain in osteoarthritis (OA). From the findings, we hope to
7 consolidate guidance on interpreting OA trials in systematic reviews based on empirical evidence
8 from Cochrane reviews.

10 **Methods and analysis**

11 Only systematic reviews that compare experimental interventions with sham, placebo, or no
12 intervention control will be considered eligible. Bias will be assessed with the risk of bias tool,
13 used according to the Cochrane Collaboration's recommendations. Furthermore, single vs.
14 multicentre trial status, trial size, and funding will be assessed. The primary outcome (pain) will be
15 abstracted from the first appearing forest plot for overall pain in the Cochrane review.

16 Treatment effect sizes (ESs) will be expressed as standardised mean differences
17 (SMDs), where the difference in mean values available from the forest plots is divided by the
18 pooled standard deviation (SD). To empirically assess the risk of bias in treatment benefits, we will
19 perform stratified analyses of the trials from the included meta-analyses and assess the
20 interaction between trial characteristics and treatment effect. A relevant study-level covariate is
21 defined as one that decreases the between-study variance (τ^2 , estimated as Tau-squared [T^2]) as a
22 consequence of inclusion in the mixed effects statistical model.

24 **Ethics and dissemination**

25 Meta-analyses and randomised controlled trials provide the most reliable basis for treatment of
26 patients with OA, but the actual impact of bias is unclear. This study will systematically examine
27 the methodological quality in OA Cochrane reviews and explore the effect estimates behind
28 possible bias. Because our study does not collect primary data, no formal ethical assessment and
29 informed consent are required.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3

Protocol registration PROSPERO (CRD42013006924)

For peer review only

1 INTRODUCTION

2 The Cochrane Musculoskeletal Group (CMSG) is one of the 53 existing review groups in the
3 Cochrane Collaboration, which aims to prepare, maintain, and disseminate high-quality systematic
4 reviews for musculoskeletal diseases including osteoarthritis; and help health care providers,
5 patients and carers to make well-informed decisions on prevention, treatment and management
6 of musculoskeletal conditions.^{1,2} (<http://musculoskeletal.cochrane.org/more-about-us> 29. Aug
7 2013). The Cochrane Collaboration makes a considerable contribution to reduce bias in scientific
8 interpretation of research.³⁻⁵ Systematic reviews founded on randomised trials provide the most
9 reliable evidence about the effects of healthcare interventions.⁶ Unfortunately, inadequate
10 methodology may distort the outcomes from systematic reviews and meta-analyses⁷ and produce
11 misleading results.⁸

12 Description of the problem or issue

13 Bias in trials can lead to underestimation or overestimation of the true intervention effect.⁹
14 Regardless of the *tools* used to assess risk of bias, the *methods* for assessing and summarising
15 potential bias and incorporating bias assessments into meta-analyses vary greatly.^{3,4} Bias
16 associated with particular characteristics of studies may be examined using meta-epidemiology,
17 which analyses a cluster of meta-analyses where the influence of the trial characteristics—such as
18 judgements on risk of bias on treatment effects estimates—is explored.⁸ By using meta-
19 epidemiologic studies, it is possible to examine the association of specific trial characteristics in a
20 collection of meta-analyses and their included trials.^{10,11}

21
22 Most meta-epidemiologic studies focus on allocation concealment and blinding and
23 their influence on treatment effects of dichotomous outcomes,^{10,12} but this study will focus on
24 other characteristics as well: attrition bias, the issue of single centre vs. multicentre trials, and
25 funding. Further, this study will focus on pain—a continuous patient reported outcome (PRO: Non-
26 drug intervention trials researching treatment in osteoarthritis are difficult to blind; the patients
27 might know whether they are receiving the intervention or control, which could affect their (self-
28 reported) pain scores.

Description of the methods being investigated

Much research has been conducted to understand bias in trials and how it may influence the results of systematic reviews.⁵ In 2001, the Cochrane Bias Methods Group was established to investigate how bias influences primary studies. Through its acknowledged work, the group developed the Cochrane risk of bias tool in 2008, based on the methodological contributions of meta-epidemiological studies. This tool has since been updated is a mandatory component of Cochrane reviews.⁴ There remain additional possible contributors to bias which are not currently standard components for the Cochrane risk of Bias tool.

At the Cochrane Methods Symposium in Quebec City, Canada, October 2013, L. Bero and J. Sterne –among others –contributed in a debate on whether or not to include funding as a standard domain in the Cochrane risk of bias tool, or if the bias related to source of funding could be captured as part of various “reporting biases,” as eligible studies tend to remain unpublished for reasons related to their “negative” results.^{13;14}

Studies have suggested that the number of study sites might have an influence on effect size.¹⁵ Single-centre trials tend to include more homogeneous populations within the (highly selected) study eligibility criteria, and they are more likely than multicentre trials to perform well in experienced teams of providers with expertise in the specific technical or other aspects of an intervention.¹⁵ However, single-centre trials risk overestimating effect sizes.¹⁵

Trial size also is known for being inversely associated with bigger effect estimates.¹⁶ This phenomenon could be a reflection of smaller trials' being prone to reporting bias: studies with statistically significant results tend to be published more frequently than those with non-significant results.¹⁷ However, the larger the trial, the greater the probability that results are published.¹⁸ Furthermore, smaller trials might tend to be more susceptible to overall bias assessed by the Cochrane risk-of-bias tool.¹⁸

Why this review is needed

Bias domains from the Cochrane risk of bias tool (selection bias, performance bias, detection bias, attrition bias, and reporting bias), and further centre status, trials size, and source of funding risk positively influencing an experimental treatment if they are found inadequate or unclear.^{11;12;16;18-}

²⁰ A meta-epidemiological study assessing binary outcomes showed that odds ratios (ORs) from

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 trials with unclear or inadequate concealment were on average 30% lower (i.e., more beneficial to
2 the intervention) than ORs from trials with adequate methodology (combined ratio of ORs 0.70,
3 95% CI 0.62 to 0.80).⁷ Results for binary outcomes may not be extrapolated to trials assessing
4 continuous outcomes because such trials usually differ in medical condition, risk of bias, sample
5 size, and statistical analysis.²¹

6 In spite of this knowledge, systematic reviews and meta-analyses still provide
7 summary data to policymakers, health care professionals, patients and their relatives to make
8 decisions about the patients' treatment and well-being. It is interesting to explore whether these
9 systematic reviews and meta-analyses provide the true effect estimates, and if all these groups are
10 making decisions on the basis of spurious (biased) effect estimates. The validity of systematic
11 reviews and meta-analysis is depending on methodological quality and unbiased dissemination of
12 trials.²² The association between methodological components and the overestimated treatment
13 effects will be determined in this meta-epidemiological study, which will enable us to provide
14 guidance on how to interpret OA trials in systematic reviews based on empirical evidence from
15 Cochrane reviews.

17 **Objectives**

18 Our objective was to evaluate the association between estimates of treatment effects with
19 different study characteristics including both well-recognised domains as well as novel bias-related
20 aspects in meta-analyses of^{10;11;15;21;23;24} used for treating pain in OA.

24 **METHODS**

25 **Protocol and registration**

26 Our protocol is registered on PROSPERO (CRD42013006924); our protocol manuscript conforms to
27 the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for
28 reporting systematic reviews and meta-analyses.²⁵

1

2 Eligibility criteria

3 Only systematic reviews of randomised or controlled trials available will be used in this analysis.

4 Only systematic reviews that compare experimental interventions with sham, placebo, or no
5 intervention control in patients with OA and which use a patient-reported pain measure as an
6 outcome will be considered eligible. Moreover, only trials where patients in both the intervention
7 and the control group receive the same treatment except from an add-on in the intervention
8 group will be eligible for inclusion. Reviews will be excluded if no relevance is found when reading
9 the title and abstract. Further exclusion will be made if the review did not report a meta-analysis
10 on pain—preferably a meta-analysis showing overall pain, including at least two trials. Two
11 reviewers will independently evaluate the reports for eligibility, and any disagreements will be
12 resolved by discussion or by involvement of a third reviewer. Data will be eligible from the trials,
13 which are included in eligible reviews and meta-analyses.

15 Search for meta-analyses and inclusion of trials

16 We will search the Cochrane Database of Systematic Reviews via the Cochrane Library for
17 osteoarthritis reviews using a combination of MeSH terms and natural language vocabulary (see
18 **Table 1**). The latest update of the Cochrane review will be used. Eligible trials will be identified
19 from the reference lists of the published Cochrane reviews.

21 **Table 1.** Search Strategy, Cochrane Library via Wiley Issue 4, 2014

Search	Terms
#1	MeSH descriptor: [Osteoarthritis] explode all trees
#2	osteoarthr*:ti,ab
#3	degenerative near/2 arthritis:ti,ab
#4	(#1 or #2 or #3)

22

23 Risk of bias in individual studies

24

25

26

27

28

29

30

31

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 ***Cochrane risk of bias tool:***

2 The risk of bias within each full-text trial will be assessed using the domains of the risk of bias tool
3 as recommended by the Cochrane Collaboration,²⁶ which comprise methods for sequence
4 generation and maintaining allocation concealment, blinding, and management of incomplete
5 outcome data. Each domain will be rated as adequate, inadequate, or unclear risk of bias (see
6 **Table 2**).

8 ***Other risk of bias items:***

9 In the course of meta-epidemiologic studies, other sources, such as significant discrepancies
10 between single vs. multicentre trials,¹⁵ small vs. large trials,¹⁸ and source of funding²⁷ arises as
11 possible risk of bias domains (see Table 2).

13 **Data collection process and data items**

14 We will use a systematic, standardised data extraction approach to gather information from all
15 eligible OA studies. The primary outcome (pain) will be abstracted from overall pain reported in
16 the Cochrane review's first pain measure forest plot. Outcome will be collected at the time point
17 closest to 12 weeks' follow-up. Two reviewers will independently extract data from the trials.

18 We anticipate that pain will be measured in various ways, and thus different instruments will be
19 applied to monitor the changes during any given trial period²⁸. Commonly pain is measured by
20 either a visual analogue scale (VAS) or a numeric rating scale (NRS) and less commonly by more
21 complex item-based instruments (e.g. WOMAC²⁹, KOOS³⁰, and ICOAP³¹).

22 ***"Systematic review-level" data extraction***

23 At the level of the systematic review, we will extract data on review ID, author, year of publication,
24 and accumulated trial size combined in the meta-analysis (i.e., N_{Total} , N_I , and N_C). Type of
25 intervention will be categorised according to the "suggested sequential, pyramid approach to
26 management of OA" by Dieppe & Lohmander³² and the *Osteoarthritis Research Society*
27 *International* (OARSI) recommendations³³ (see, **Table 3**, OA intervention categories).

29 ***"Trial-level" data extraction***

1 At the trial level, we will assign studies a trial ID and extract information on author name, year of
 2 publication, type of pain measure, type of intervention, and type of OA condition. From the forest
 3 plot available in the included review, we will extract the following study-level covariates: mean
 4 values (m_i and m_c), standard deviations (sd_i and sd_c) and size of the trials.

5 **Table 2.** Risk of bias assessment table

Bias domain	Bias item	Review authors judgment (adequate, inadequate, or unclear)
Selection Bias	Sequence generation	Sequence generation will be regarded as adequate if a random approach in the sequence generation process –referred to as a random number table, a random computer-generated number, coin tossing, drawing of lots, shuffling cards, or throwing dice—is described. Date of inclusion or admission, or record number of clinic/hospital will be considered inadequate. Deficient information about the process will be considered as unclear.
	Allocation concealment	Allocation concealment will be regarded as adequate if sequentially numbered, sealed, opaque envelopes, numbered or coded medical containers, or a centralised randomisation is applied. If it is possible to predict the assignment, allocation concealment will be regarded as inadequate. Therefore, date of birth, application of an open random allocation schedule, or any other explicitly unconcealed procedure will be regarded as inadequate. The allocation concealment will be regarded as unclear if the method of concealment is not available.
Performance Bias	Blinding of participants	Blinding of patients will be regarded as adequate if intervention and control treatment are described as indistinguishable, or if it is unlikely that the blinding could have been broken for both patients and data collectors. Deficient information about the blinding process will be considered as unclear.
Detection bias	Blinding of key study personnel	Blinding of key study personnel will be regarded as adequate if intervention and control treatment are described as indistinguishable, or if it is unlikely that the blinding could have been broken for data collectors and key study personnel. Deficient information about the blinding process will be considered as unclear.
Attrition bias	Incomplete outcome data	Data will be regarded as adequate (complete) if there are no missing outcome data or if the missing data constitute less than 10% of total number of participants at baseline and if no differences in reasons for dropout were observed between the groups. Further, outcome data will be considered adequate if missing data have been imputed using appropriate statistical methods like intention to treat (ITT). Deficient information about the blinding process will be regarded as unclear.
Other bias	Centre status	A trial will be considered a multicentre trial if more than one centre is involved. In case of missing information, the trial will be classified as multicentre if it reports both several ethics committees and different affiliations of authors. If the report stated both a single ethics committee and a single author affiliation, the trial will be classified as a single centre. Information about single- and multicentre trials will be extracted from the text, statements, author's affiliations, and acknowledgement in every included trial.
	Trial size	To judge whether a trial is small or large, we will use a threshold of 128 participants. If the total number of randomised participants is less than 128 patients (according to the Cochrane review), the study will be regarded as a small trial; trials with ≥ 128 participants will be referred to as large trials. The threshold of 64 participants in each group corresponds to a reasonable power (80%) to detect a standardised mean difference (SMD) ≥ 0.5 . ³⁴
	Funding	Trials will be specified either as being funded by for-profit funding or non-profit funding. Non-profit funding includes money received from both non-profit organizations (e.g., Internal hospital funding and governmental funding) and not funded trials. For-profit organizations will be defined as companies that might acquire financial gain or loss depending on the outcome of the trial. Further, trials with a mix of for-profit and non-profit or if the funding is not reported, will be considered as for-profit funded. Funding is defined as including provision of manpower (authorship, statistical analysis, or other assistance), study materials (drug, placebo, assay kits, or similar materials), or grants. ²⁷

Sources of funding will be extracted from the text, statements of sources of support, authors' affiliations, acknowledgments, and trial registration, if available.

1

2 The size of the study will be handled in two ways: (i) trial size according to the meta-analysis (i.e.,
3 forest plot, n_i and n_c), and (ii) trial size according to the original (ITT) population according to the
4 trial report (N_i and N_c). Further, we will assess the following characteristics from the trials:
5 attrition rate during the trial (a_{Total} , a_i , and a_c), and trial duration (weeks). Further, we will extract
6 information on the comparator groups applied in each trial, whether placebo/sham or waiting-
7 list/nothing.

8

9 **Table 3** Intervention categories

Non-pharmacological modalities of treatment (NP)	Pharmacological modalities of treatment (P)	Surgical modalities of treatment (S)
a) General information and advice (education, regular contact with caregiver, lifestyle alterations, etc.) b) Exercise and therapy (physical and occupational therapy, aerobic, muscle strength, ROM training, water exercise, etc.) c) Weight loss d) Walking and other aids (e.g., canes, wheeled walkers, assistive technology such as orthoses, braces, insoles) e) Thermal modalities, transcutaneous electrical nerve stimulation (TENS), acupuncture, etc.	f) Paracetamol (acetaminophen) g) NSAIDs (topical or oral) h) Intra-articular injections with corticosteroids or hyaluronate i) Nutraceuticals (e.g., glucosamine, chondroitin sulphate, rosehip powder) j) Opioids (weak: tramadol, codeine etc.; stronger: morphine, etc.)	k) Surgery (joint preserving; osteotomy and resurfacing and partial or total joint replacement)

10

1 **Data synthesis**

2 Treatment effect sizes (ES) will be expressed as SMD by dividing the difference in mean values
3 available from the forest plots by the SD. Negative effect sizes will indicate a beneficial effect of
4 the experimental intervention (i.e., pain reduction). We will register whether the data are
5 expressed as values from follow-up, change from baseline, or a mix, as studies have shown that
6 there is no relevant difference between follow-up and change data SMDs in meta-analysis.³⁵ To
7 explore whether the choice of pain instrument (i.e., VAS, NRS, or item-based scores) interacts with
8 the apparent treatment effect, we will also combine SMDs derived from each of these instrument
9 categories, in a stratified meta-analysis. This will reveal whether there are any relevant differences
10 in effect sizes depending on the pain-instrument chosen. To address the effects of trial size in
11 addition to the categorisation of small and large trials we will do funnel plots based on sample
12 sizes. If small study effects are present, funnel plots will be asymmetrical.

13 **Statistical analysis**

14 To empirically assess the risk of bias in the treatment effects in reviews, we will perform stratified
15 analyses across trials according to all the different extracted trial characteristics and derive P-
16 values for interaction between trial characteristics and treatment effect. Within each systematic
17 review, the ES for trial effects according to the different risk of bias assessments will be estimated
18 by using a random effect meta-analysis model. The differences between the pooled estimates will
19 be derived and combined using random effect meta-analysis fully allowing for heterogeneity, to
20 measure the variability in bias estimates, expressed in τ^2 . A relevant study-level covariate is
21 defined as one that decreases the between-study variance (τ^2 , estimated as Tau-squared [T^2]) as a
22 consequence of inclusion in the mixed-effects statistical model. All the statistical meta-regression
23 analyses will be based on REstricted Maximum Likelihood (REML) (i.e., random-effects) models;³⁶
24 models will be developed and analysed using SAS software (version 9.2, by SAS Institute Inc., Cary,
25 NC, USA).

27 **ETHICS AND DISSEMINATION**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 We believe that the findings of this meta-epidemiological study will have important implications
2 for future research strategies and implementation of study conclusions. Meta-analyses and
3 randomised controlled trials provide the most reliable basis for treating patients with OA.
4 However, even though the influence of bias items is well known and described, authors tend to
5 forget that biased trials included in systematic reviews will cause meta-analyses to be biased.³⁷

6 Therefore, it is essential that those who conduct systematic reviews be familiar with
7 the potential biases within primary studies and how such biases could influence review results and
8 the ensuing conclusions. Still, many Cochrane review authors are reluctant or fail to incorporate
9 the risk of bias assessment in their analysis and conclusions,³⁸ compromising the trustworthiness
10 of results from meta-analysis derived from these reviews. Although the Cochrane Collaboration
11 has changed the way it assesses bias in included trials⁵ owing to Ken Schulz's work on bias
12 assessment,²³ the Cochrane risk of bias tool in 2008,⁴ AMSTAR (Assessing the methodological
13 quality of systematic reviews checklist),³⁹ and the grading of recommendations assessment,
14 development and evaluation (GRADE) approach,⁴⁰ meta-analyses might still overestimate the
15 effect estimates from biased studies.

16 As previously described by Nüesch et al the presence and extent of small study
17 effects in OA research might distort the overall evidence from meta-analyses¹⁶. Thus the influence
18 of small trials on estimated treatment effects might be considered a novel risk of bias domain that
19 needs to be addressed in the future. However, one of the reasons why small studies may give
20 different answers from larger studies is that the participants in small studies may be more
21 homogeneous than those in larger studies. Thus changes with treatment may be more similar, and
22 if they are a more severely affected group the potential for gain may be larger. This work will
23 facilitate consensus on the need for mandatory sensitivity analyses before making conclusions of a
24 meta-analysis if the overall result is not consistent with those of the largest trials.¹⁸

26 After two decades of assessing risk of bias, it is clearly time we examine whether the
27 tool for assessing risk of bias is complete³⁸ What items should be added or removed? Which items
28 have the greatest impact on estimates of effect? This study will examine the evidence in CMSG
29 reviews using patient reported outcomes from OA trials as an example and explore the true

1 implications on effect estimates behind the possible shades of bias. As this study collects no
2 primary data, no additional formal ethical assessment and informed consent are required.

3

4 **Acknowledgement**

5 We thank the Parker Institute, Frederiksberg Hospital, and The Oak Foundation for creating the
6 possibility and right settings for this research. Additionally, we thank the Cochrane
7 Musculoskeletal Group Editorial based at The University of Ottawa, Centre for Global Health.

8

9 **Contributors**

10 JBH, RC, CBJ, PT, and HL conceived and designed the study, and JBH, RC, and CBJ contributed to
11 the development of the protocol. All of the authors (JBH, CBJ, IB, PT, EG, JPP, TR, GAW, AM, LM,
12 HL, and RC) assisted in the final protocol and agreed to its final approval before submission.

13

14 **Funding**

15 This research received no specific grant from any funding agency in the public, commercial, or not-
16 for-profit sectors. This research was funded by The Oak Foundation, which had no role in study
17 design, data collection, data synthesis, data interpretation, writing the report, or the decision to
18 submit the manuscript for publication.

19

20 **Competing interests**

21 This study had no financial competing interests. The Parker Institute's Musculoskeletal Statistics
22 Unit is grateful for the financial support received from public and private foundations, companies,
23 and private individuals over the years. The Parker Institute is supported by a core grant from the
24 Oak Foundation; The Oak Foundation is a group of philanthropic organizations that, since its
25 establishment in 1983, has given grants to not-for-profit organisations around the world.

26

27 All the authors are involved with different health care initiatives and research (including Cochrane,
28 OMERACT, and the GRADE Working Group) that could benefit from wide uptake of this
29 publication.

30

1
2
3
4 **1 REFERENCES**

- 5
6
7 (1) Maxwell L, Santesso N, Tugwell PS, et al. Method guidelines for Cochrane Musculoskeletal
8 Group systematic reviews. *J Rheumatol* 2006; 33(11):2304-2311.
- 9
10 (2) Ghogomu EA, Maxwell LJ, Buchbinder R, Rader T, Pardo PJ, Johnston RV et al. Updated
11 method guidelines for cochrane musculoskeletal group systematic reviews and
12 metaanalyses. *J Rheumatol* 2014; 41(2):194-205.
- 13
14 (3) Lundh A, Gotzsche PC. Recommendations by Cochrane Review Groups for assessment of
15 the risk of bias in studies. *BMC Med Res Methodol* 2008; 8:22.
- 16
17 (4) Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing
18 risk of bias in randomised trials. *BMJ* 2011; 343:d5928.
- 19
20 (5) Turner L, Boutron I, Hrobjartsson A, et al. The evolution of assessing bias in Cochrane
21 systematic reviews of interventions: celebrating methodological contributions of the
22 Cochrane Collaboration. *Syst Rev* 2013; 2:79.
- 23
24 (6) Mulrow CD. The medical review article: state of the science. *Ann Intern Med* 1987;
25 106(3):485-488.
- 26
27 (7) Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of
28 controlled clinical trials. *BMJ* 2001; 323(7303):42-46.
- 29
30 (8) Sterne JA, Juni P, Schulz KF, et al. Statistical methods for assessing the influence of study
31 characteristics on treatment effects in 'meta-epidemiological' research. *Stat Med* 2002;
32 21(11):1513-1524.
- 33
34 (9) Gluud LL. Bias in clinical intervention research. *Am J Epidemiol* 2006; 163(6):493-501.
- 35
36 (10) Savovic J, Jones H, Altman D, et al. Influence of reported study design characteristics on
37 intervention effect estimates from randomised controlled trials: combined analysis of
38 meta-epidemiological studies. *Health Technol Assess* 2012; 16(35):1-82.
- 39
40 (11) Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates
41 in controlled trials with different interventions and outcomes: meta-epidemiological study.
42 *BMJ* 2008; 336(7644):601-605.
- 43
44 (12) Nuesch E, Reichenbach S, Trelle S, et al. The importance of allocation concealment and
45 patient blinding in osteoarthritis trials: a meta-epidemiologic study. *Arthritis Rheum* 2009;
46 61(12):1633-1641.
- 47
48 (13) Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard
49 item. *Cochrane Database of Systematic Reviews* 2013.
- 50
51 (14) Sterne JAC. Why the Cochrane risk of bias tool should not include funding source as a
52 standard item [editorial]. *Cochrane Database of Systematic Reviews* 2013.
- 53
54
55
56
57
58
59
60

- 1
2
3
4 1 (15) Dechartres A, Boutron I, Trinquart L, et al. Single-center trials show larger treatment
5 2 effects than multicenter trials: evidence from a meta-epidemiologic study. *Ann Intern Med*
6 3 2011; 155(1):39-51.
7
8
9 4 (16) Nuesch E, Trelle S, Reichenbach S, et al. Small study effects in meta-analyses of
10 5 osteoarthritis trials: meta-epidemiological study. *BMJ* 2010; 341:c3515.
11
12 6 (17) Dwan K, Altman DG, Arnaiz JA, et al. Systematic review of the empirical evidence of study
13 7 publication bias and outcome reporting bias. *PLoS One* 2008; 3(8):e3081.
14
15 8 (18) Dechartres A, Trinquart L, Boutron I, et al. Influence of trial sample size on treatment
16 9 effect estimates: meta-epidemiological study. *BMJ* 2013; 346:f2304.
17
18 10 (19) Lundh A, Sismondo S, Lexchin J, et al. Industry sponsorship and research outcome.
19 11 *Cochrane Database Syst Rev* 2012; 12:MR000033.
20
21
22 12 (20) Nuesch E, Trelle S, Reichenbach S, et al. The effects of excluding patients from the analysis
23 13 in randomised controlled trials: meta-epidemiological study. *BMJ* 2009; 339:b3244.
24
25 14 (21) Bafeta A, Dechartres A, Trinquart L, et al. Impact of single centre status on estimates of
26 15 intervention effects in trials with continuous outcomes: meta-epidemiological study. *BMJ*
27 16 2012; 344:e813.
28
29 17 (22) Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of
30 18 therapy. I: Medical. *Stat Med* 1989; 8(4):441-454.
31
32
33 19 (23) Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of
34 20 methodological quality associated with estimates of treatment effects in controlled trials.
35 21 *JAMA* 1995; 273(5):408-412.
36
37 22 (24) Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies
38 23 between large and small randomized trials in meta-analyses. *Ann Intern Med* 2001;
39 24 135(11):982-989.
40
41
42 25 (25) Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic
43 26 reviews and meta-analyses of studies that evaluate healthcare interventions: explanation
44 27 and elaboration. *BMJ* 2009; 339:b2700.
45
46 28 (26) Higgins JPT, Altman D, Sterne JA. Chapter 8: Assessing risk of bias in included studies.
47 29 *Cochrane Handbook for Systematic Reviews of Interventions*. Cochrane Handbook for
48 30 *Systematic Reviews of Interventions* ed. 2011.
49
50
51 31 (27) Als-Nielsen B, Chen W, Gluud C, et al. Association of funding and conclusions in randomized
52 32 drug trials: a reflection of treatment effect or adverse events? *JAMA* 2003; 290(7):921-928.
53
54 33 (28) Juhl C, Lund H, Roos EM, et al. A hierarchy of patient-reported outcomes for meta-analysis
55 34 of knee osteoarthritis trials: empirical evidence from a survey of high impact journals.
56 35 *Arthritis* 2012; 2012:136245.
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- (29) Bellamy N. The WOMAC Knee and Hip Osteoarthritis Indices: development, validation, globalization and influence on the development of the AUSCAN Hand Osteoarthritis Indices. *Clin Exp Rheumatol* 2005; 23(5 Suppl 39):S148-S153.
- (30) Roos EM, Roos HP, Lohmander LS, et al. Knee Injury and Osteoarthritis Outcome Score (KOOS)--development of a self-administered outcome measure. *J Orthop Sports Phys Ther* 1998; 28(2):88-96.
- (31) Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). *Arthritis Care Res (Hoboken)* 2011; 63 Suppl 11:S240-S252.
- (32) Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. *Lancet* 2005; 365(9463):965-973.
- (33) Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage* 2008; 16(2):137-162.
- (34) Norman GR, Sloan JA, Wyrwich KW. The truly remarkable universality of half a standard deviation: confirmation through another look. *Expert Rev Pharmacoecon Outcomes Res* 2004; 4(5):581-585.
- (35) da Costa BR, Nuesch E, Rutjes AW, et al. Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study. *J Clin Epidemiol* 2013; 66(8):847-855.
- (36) Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? *Stat Med* 2002; 21(11):1559-1573.
- (37) Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). *J Clin Epidemiol* 2011; 64(4):407-415.
- (38) Hrobjartsson A, Boutron I, Turner L, et al. Assessing risk of bias in randomised clinical trials included in Cochrane Reviews: the why is easy, the how is a challenge. *Cochrane Database Syst Rev* 2013; 4:ED000058.
- (39) Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol* 2007; 7:10.
- (40) Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336(7650):924-926.

Assessing bias in osteoarthritis trials included in Cochrane reviews:

Protocol for a meta-epidemiological study

Julie B. Hansen,^{1,2} Carsten B. Juhl,² Isabelle Boutron,^{3,4} Peter Tugwell,⁵ Elizabeth Ghogomu,⁶ Jordi Pardo Pardo,⁷ Tamara Rader,⁶ George A. Wells,⁸ Alain Mayhew,^{4,9} Lara Maxwell,⁶ Hans Lund,² Robin Christensen,^{1,2} and The Editorial Board of the Cochrane Musculoskeletal Group.

1: Musculoskeletal Statistics Unit, The Parker Institute, Dept. Rheum., Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark.

2: SEARCH research group, Research Unit of Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

3: NSERM, University Paris Descartes, Paris, France

4: Cochrane Bias Methods Group, Ottawa, Canada

5: Ottawa Hospital Research Institute, Joint Coordinating Editor CMSG

6: Cochrane Musculoskeletal Group, University of Ottawa

7: Centre for Global Health, University of Ottawa

8: Epidemiology and Community Medicine, University of Ottawa

9: Ottawa Hospital Research Institute, Centre for Practice-Changing Research, Ottawa, Canada

Correspondence to:

Robin Christensen, BSc, MSc, PhD; senior biostatistician

Head of Musculoskeletal Statistics Unit,

The Parker Institute, Department of Rheumatology,

Copenhagen University Hospital, Bispebjerg and Frederiksberg,

Nordre Fasanvej 57

DK-2000 Copenhagen F

Denmark

Phone: (+45) 3816 4165

Fax: (+45) 3816 4159

E-mail: Robin.Christensen@frh.regionh.dk

Keywords: osteoarthritis, meta-analysis, meta-epidemiology, risk of bias

Word count (excl. title page, abstract and references): 2286

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 1
29
30 2
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author	E-mail address
JBH	juliebolvig@gmail.com
CBJ	cjuhl@health.sdu.dk
IB	isabelle.boutron@htd.aphp.fr
PT	Tugwell.BB@uOttawa.ca
EG	cmsg@uottawa.ca
JPP	jpardo@uottawa.ca
TR	trader@uottawa.ca
GAW	gawells@ottawaheart.ca
AM	almayhew@ohri.ca
LM	lmaxwell@uottawa.ca
HL	hlund@health.sdu.dk
RC	Robin.Christensen@frh.regionh.dk

1 2 3 4 5 6 7 8 **ABSTRACT**

9 10 **Introduction**

11 3 The validity of systematic reviews and meta-analysis depends on methodological quality and
12 4 unbiased dissemination of trials. Our objective is to evaluate the association of estimates of
13 5 treatment effects with different bias-related study characteristics in meta-analyses of
14 6 interventions used for treating pain in osteoarthritis (OA). From the findings, we hope to
15 7 consolidate guidance on interpreting OA trials in systematic reviews based on empirical evidence
16 8 from Cochrane reviews.

17 18 19 20 21 22 **Methods and analysis**

23 10 Only systematic reviews that compare experimental interventions with sham, placebo, or no
24 11 intervention control will be considered eligible. Bias will be assessed with the risk of bias tool,
25 12 used according to the Cochrane Collaboration's recommendations. Furthermore, single vs.
26 13 multicentre trial status, trial size, and funding will be assessed. The primary outcome (pain) will be
27 14 abstracted from the first appearing forest plot for overall pain in the Cochrane review.

28 15
29 16 Treatment effect sizes (ESs) will be expressed as standardised mean differences
30 17 (SMDs), where the difference in mean values available from the forest plots is divided by the
31 18 pooled standard deviation (SD). To empirically assess the risk of bias in treatment benefits, we will
32 19 perform stratified analyses of the trials from the included meta-analyses and assess the
33 20 interaction between trial characteristics and treatment effect. A relevant study-level covariate is
34 21 defined as one that decreases the between-study variance (τ^2 , estimated as Tau-squared [T^2]) as a
35 22 consequence of inclusion in the mixed effects statistical model.


36 37 38 39 40 41 42 43 44 **Ethics and dissemination**

45 24 Meta-analyses and randomised controlled trials provide the most reliable basis for treatment of
46 25 patients with OA, but the actual impact of bias is unclear. This study will systematically examine
47 26 the methodological quality in OA Cochrane reviews and explore the effect estimates behind
48 27 possible bias. Because our study does not collect primary data, no formal ethical assessment and
49 28 informed consent are required.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 **Protocol registration** PROSPERO (CRD42013006924)
3

For peer review only



4

INTRODUCTION

The Cochrane Musculoskeletal Group (CMSG) is one of the 53 existing review groups in the Cochrane Collaboration, which aims to prepare, maintain, and disseminate high-quality systematic reviews for musculoskeletal diseases including osteoarthritis; and help health care providers, patients and carers to make well-informed decisions on prevention, treatment and management of musculoskeletal conditions.^{1,2} (<http://musculoskeletal.cochrane.org/more-about-us> 29. Aug 2013). The Cochrane Collaboration makes a considerable contribution to reduce bias in scientific interpretation of research.³⁻⁵ Systematic reviews founded on randomised trials provide the most reliable evidence about the effects of healthcare interventions.⁶ Unfortunately, inadequate methodology may distort the outcomes from systematic reviews and meta-analyses⁷ and produce misleading results.⁸

Description of the problem or issue

Bias in trials can lead to underestimation or overestimation of the true intervention effect.⁹ Regardless of the *tools* used to assess risk of bias, the *methods* for assessing and summarising potential bias and incorporating bias assessments into meta-analyses vary greatly.^{3,4} Bias associated with particular characteristics of studies may be examined using meta-epidemiology, which analyses a cluster of meta-analyses where the influence of the trial characteristics—such as judgements on risk of bias on treatment effects estimates—is explored.⁸ By using meta-epidemiologic studies, it is possible to examine the association of specific trial characteristics in a collection of meta-analyses and their included trials.^{10,11}

Most meta-epidemiologic studies focus on allocation concealment and blinding and their influence on treatment effects of dichotomous outcomes,^{10,12} but this study will focus on other characteristics as well: attrition bias, [reporting bias](#), the issue of single centre vs. multicentre trials, and funding. Further, this study will focus on pain—a continuous patient reported outcome (PRO: Non-drug intervention trials researching treatment in osteoarthritis are difficult to blind; the patients might know whether they are receiving the intervention or control, which could affect their (self-reported) pain scores.

Formatted: Font color: Blue

Description of the methods being investigated

Much research has been conducted to understand bias in trials and how it may influence the results of systematic reviews.⁵ In 2001, the Cochrane Bias Methods Group was established to investigate how bias influences primary studies. Through its acknowledged work, the group developed the Cochrane risk of bias tool in 2008, based on the methodological contributions of meta-epidemiological studies. This tool has since been updated is a mandatory component of Cochrane reviews.⁴ There remain additional possible contributors to bias which are not currently standard components for the Cochrane risk of Bias tool.

At the Cochrane Methods Symposium in Quebec City, Canada, October 2013, L. Bero and J. Sterne –among others –contributed in a debate on whether or not to include funding as a standard domain in the Cochrane risk of bias tool, or if the bias related to source of funding could be captured as part of various “reporting biases,” as eligible studies tend to remain unpublished for reasons related to their “negative” results.^{13;14}

Studies have suggested that the number of study sites might have an influence on effect size.¹⁵ Single-centre trials tend to include more homogeneous populations within the (highly selected) study eligibility criteria, and they are more likely than multicentre trials to perform well in experienced teams of providers with expertise in the specific technical or other aspects of an intervention.¹⁵ However, single-centre trials risk overestimating effect sizes.¹⁵

Trial size also is known for being inversely associated with bigger effect estimates.¹⁶ This phenomenon could be a reflection of smaller trials' being prone to reporting bias: studies with statistically significant results tend to be published more frequently than those with non-significant results.¹⁷ However, the larger the trial, the greater the probability that results are published.¹⁸ Furthermore, smaller trials might tend to be more susceptible to overall bias assessed by the Cochrane risk-of-bias tool.¹⁸

Why this review is needed

Bias domains from the Cochrane risk of bias tool (selection bias, performance bias, detection bias, attrition bias, and reporting bias), and further centre status, trials size, and source of funding risk positively influencing an experimental treatment if they are found inadequate or unclear.^{11;12;16;18-}

²⁰ A meta-epidemiological study assessing binary outcomes showed that odds ratios (ORs) from

Formatted: Font color: Blue

Formatted: Font color: Blue

Formatted: Font color: Blue

Formatted: Font color: Blue

1
2
3
4
5
6
7
8 1 trials with unclear or inadequate concealment were on average 30% lower (i.e., more beneficial to
9 2 the intervention) than ORs from trials with adequate methodology (combined ratio of ORs 0.70,
10 3 95% CI 0.62 to 0.80).⁷ Results for binary outcomes may not be extrapolated to trials assessing
11 4 continuous outcomes because such trials usually differ in medical condition, risk of bias, sample
12 5 size, and statistical analysis.²¹

13 6 In spite of this knowledge, systematic reviews and meta-analyses still provide
14 7 summary data to policymakers, health care professionals, patients and their relatives to make
15 8 decisions about the patients' treatment and well-being. It is interesting to explore whether these
16 9 systematic reviews and meta-analyses provide the true effect estimates, and if all these groups are
17 10 making decisions on the basis of spurious (biased) effect estimates. The validity of systematic
18 11 reviews and meta-analysis is depending on methodological quality and unbiased dissemination of
19 12 trials.²² The association between methodological components and the overestimated treatment
20 13 effects will be determined in this meta-epidemiological study, which will enable us to provide
21 14 guidance on how to interpret OA trials in systematic reviews based on empirical evidence from
22 15 Cochrane reviews.

32 17 Objectives

33
34 18 [Our objective was to evaluate the association between estimates of treatment effects with](#)
35 19 [different study characteristics including both well-recognised domains as well as novel bias-related](#)
36 20 [aspects in meta-analyses of ^{10;11;15;21;23;24} used for treating pain in OA.](#)

37 21
38 22 ~~[Our objective is to evaluate the association between estimates of treatment effects with different](#)~~
39 23 ~~[bias-related study characteristics\(Schulz, 1995-19 /id;Wood, 2008-2 /id;Savovic, 2012-1](#)~~
40 24 ~~[/id;Dechartres, 2011-7 /id;Bafeta, 2012-20 /id;Kjaergard, 2001-22 /id\) in meta-analyses of](#)~~
41 25 ~~[interventions used for treating OA pain.](#)~~

48 27 METHODS

50 28 Protocol and registration

51 29 Our protocol is registered on PROSPERO (CRD42013006924); our protocol manuscript conforms to
52
53
54
55
56
57
58
59
60

the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting systematic reviews and meta-analyses.²⁵

Eligibility criteria

Only systematic reviews of randomised or controlled trials available will be used in this analysis.

Only systematic reviews that compare experimental interventions with sham, placebo, or no intervention control in patients with OA and which use a patient-reported pain measure as an outcome will be considered eligible. Moreover, only trials where patients in both the intervention and the control group receive the same treatment except from an add-on in the intervention group will be eligible for inclusion. Reviews will be excluded if no relevance is found when reading the title and abstract. Further exclusion will be made if the review did not report a meta-analysis on pain—preferably a meta-analysis showing overall pain, including at least two trials. Two reviewers will independently evaluate the reports for eligibility, and any disagreements will be resolved by discussion or by involvement of a third reviewer. Data will be eligible from the trials, which are included in eligible reviews and meta-analyses.

Search for meta-analyses and inclusion of trials

We will search the Cochrane Database of Systematic Reviews via the Cochrane Library for osteoarthritis reviews using a combination of MeSH terms and natural language vocabulary (see **Table 1**). The latest update of the Cochrane review will be used. Eligible trials will be identified from the reference lists of the published Cochrane reviews.

Table 1. Search Strategy, Cochrane Library via Wiley Issue 4, 2014

Search	Terms
#1	MeSH descriptor: [Osteoarthritis] explode all trees
#2	osteoarth*:ti,ab

#3 degenerative near/2 arthritis:ti,ab

#4 (#1 or #2 or #3)

Risk of bias in individual studies

Cochrane risk of bias tool:

The risk of bias within each full-text trial will be assessed using the domains of the risk of bias tool as recommended by the Cochrane Collaboration,²⁶ which comprise methods for sequence generation and maintaining allocation concealment, blinding, and management of incomplete outcome data. Each domain will be rated as adequate, inadequate, or unclear risk of bias (see **Table 2**).

Other risk of bias items:

In the course of meta-epidemiologic studies, other sources, such as significant discrepancies between single vs. multicentre trials,¹⁵ small vs. large trials,¹⁸ and source of funding²⁷ arises as possible risk of bias domains (see Table 2).

Data collection process and data items

We will use a systematic, standardised data extraction approach to gather information from all eligible OA studies. The primary outcome (pain) will be abstracted from overall pain reported in the Cochrane review's first pain measure forest plot. Outcome will be collected at the time point closest to 12 weeks' follow-up. Two reviewers will independently extract data from the trials.

We anticipate that pain will be measured in various ways, and thus different instruments will be applied to monitor the changes during any given trial period²⁸. Commonly pain is measured by either a visual analogue scale (VAS) or a numeric rating scale (NRS) and less commonly by more complex item-based instruments (e.g. WOMAC²⁹, KOOS³⁰, and ICOAP³¹).

"Systematic review-level" data extraction

Formatted: Font: (Default) Calibri, 12 pt, Font color: Custom Color(RGB(35,31,32))

Formatted: Font: (Default) Calibri, 12 pt, Font color: Custom Color(RGB(35,31,32))

Formatted: Font: (Default) Calibri, 12 pt, Font color: Custom Color(RGB(35,31,32))

Formatted: Font: (Default) Calibri, 12 pt, Font color: Custom Color(RGB(35,31,32))

Formatted: Font: (Default) Calibri, 12 pt, Font color: Custom Color(RGB(35,31,32))

Formatted: Font: (Default) Calibri, 12 pt, Font color: Custom Color(RGB(35,31,32))

Formatted: Font: (Default) Calibri, 12 pt, Font color: Custom Color(RGB(35,31,32))

Formatted: Font: (Default) Calibri, 12 pt, Font color: Custom Color(RGB(35,31,32))

Formatted: Font: (Default) Calibri, 12 pt, Font color: Custom Color(RGB(35,31,32))

Formatted: Font: (Default) Calibri, Font color: Custom Color(RGB(35,31,32)), English (U.K.)

At the level of the systematic review, we will extract data on review ID, author, year of publication, and accumulated trial size combined in the meta-analysis (i.e., N_{Total} , N_i , and N_c). Type of intervention will be categorised according to the "suggested sequential, pyramid approach to management of OA" by Dieppe & Lohmander³² and the *Osteoarthritis Research Society International* (OARSI) recommendations³³ (see, **Table 3**, OA intervention categories).

"Trial-level" data extraction

At the trial level, we will assign studies a trial ID and extract information on author name, year of publication, type of pain measure, type of intervention, and type of OA condition. From the forest plot available in the included review, we will extract the following study-level covariates: mean values (m_i and m_c), standard deviations (sd_i and sd_c) and size of the trials.

Table 2. Risk of bias assessment table

Bias domain	Bias item	Review authors judgment (adequate, inadequate, or unclear)
Selection Bias	Sequence generation	Sequence generation will be regarded as adequate if a random approach in the sequence generation process –referred to as a random number table, a random computer-generated number, coin tossing, drawing of lots, shuffling cards, or throwing dice—is described. Date of inclusion or admission, or record number of clinic/hospital will be considered inadequate. Deficient information about the process will be considered as unclear.
	Allocation concealment	Allocation concealment will be regarded as adequate if sequentially numbered, sealed, opaque envelopes, numbered or coded medical containers, or a centralised randomisation is applied. If it is possible to predict the assignment, allocation concealment will be regarded as inadequate. Therefore, date of birth, application of an open random allocation schedule, or any other explicitly unconcealed procedure will be regarded as inadequate. The allocation concealment will be regarded as unclear if the method of concealment is not available.
Performance Bias	Blinding of participants	Blinding of patients will be regarded as adequate if intervention and control treatment are described as indistinguishable, or if it is unlikely that the blinding could have been broken for both patients and data collectors. Deficient information about the blinding process will be considered as unclear.
Detection bias	Blinding of key study personnel	Blinding of key study personnel will be regarded as adequate if intervention and control treatment are described as indistinguishable, or if it is unlikely that the blinding could have been broken for data collectors and key study personnel. Deficient information about the blinding process will be considered as unclear.
Attrition bias	Incomplete outcome data	Data will be regarded as adequate (complete) if there are no missing outcome data or if the missing data constitute less than 10% of total number of participants at baseline and if no differences in reasons for dropout were observed between the groups. Further, outcome data will be considered adequate if missing data have been imputed using appropriate statistical methods like intention to treat (ITT). Deficient information about the blinding process will be regarded as unclear.
Other bias	Centre status	A trial will be considered a multicentre trial if more than one centre is involved. In case of missing information, the trial will be classified as multicentre if it reports both several ethics committees and different affiliations of authors. If the report stated both a single ethics committee and a single author affiliation, the trial will be classified as a single centre. Information about single- and multicentre trials will be extracted from the text, statements, author's affiliations, and acknowledgement in every included trial.

Trial size	To judge whether a trial is small or large, we will use a threshold of 128 participants. If the total number of randomised participants is less than 128 patients (according to the Cochrane review), the study will be regarded as a small trial; trials with ≥ 128 participants will be referred to as large trials. The threshold of 64 participants in each group corresponds to a reasonable power (80%) to detect a standardised mean difference (SMD) ≥ 0.5 . ³⁴
Funding	Trials will be specified either as being funded by for-profit funding or non-profit funding. Non-profit funding includes money received from both non-profit organizations (e.g., Internal hospital funding and governmental funding) and not funded trials. For-profit organizations will be defined as companies that might acquire financial gain or loss depending on the outcome of the trial. Further, trials with a mix of for-profit and non-profit or if the funding is not reported, will be considered as for-profit funded. Funding is defined as including provision of manpower (authorship, statistical analysis, or other assistance), study materials (drug, placebo, assay kits, or similar materials), or grants. ²⁷ Sources of funding will be extracted from the text, statements of sources of support, authors' affiliations, acknowledgments, and trial registration, if available.

The size of the study will be handled in two ways: (i) trial size according to the meta-analysis (i.e., forest plot, n_i and n_c), and (ii) trial size according to the original (ITT) population according to the trial report (N_i and N_c). Further, we will assess the following characteristics from the trials: attrition rate during the trial (a_{Total} , a_i , and a_c), and trial duration (weeks). Further, we will extract information on the comparator groups applied in each trial, whether placebo/sham or waiting-list/nothing.

Table 3 Intervention categories

Non-pharmacological modalities of treatment (NP)	Pharmacological modalities of treatment (P)	Surgical modalities of treatment (S)
a) General information and advice (education, regular contact with caregiver, lifestyle alterations, etc.)		
b) Exercise and therapy (physical and occupational therapy, aerobic, muscle strength, ROM training, water exercise, etc.)		
c) Weight loss		
d) Walking and other aids (e.g., canes, wheeled walkers, assistive technology such as orthoses, braces, insoles)		
e) Thermal modalities, transcutaneous electrical nerve stimulation (TENS), acupuncture, etc.		
	f) Paracetamol (acetaminophen)	
	g) NSAIDs (topical or oral)	
	h) Intra-articular injections with	

	corticosteroids or hyaluronate	
i)	Nutraceuticals (e.g., glucosamine, chondroitin sulphate, rosehip powder)	
j)	Opioids (weak: tramadol, codeine etc.; stronger: morphine, etc.)	
		k) Surgery (joint preserving; osteotomy and resurfacing and partial or total joint replacement)

Data synthesis

Treatment effect sizes (ES) will be expressed as SMD by dividing the difference in mean values available from the forest plots by the SD. Negative effect sizes will indicate a beneficial effect of the experimental intervention (i.e., pain reduction). We will register whether the data are expressed as values from follow-up, change from baseline, or a mix, as studies have shown that there is no relevant difference between follow-up and change data SMDs in meta-analysis.³⁵ To explore whether the choice of pain instrument (i.e., VAS, NRS, or item-based scores) interacts with the apparent treatment effect, we will also combine SMDs derived from each of these instrument categories, in a stratified meta-analysis. This will reveal whether there are any relevant differences in effect sizes depending on the pain-instrument chosen. To address the effects of trial size in addition to the categorisation of small and large trials we will do funnel plots based on sample sizes. If small study effects are present, funnel plots will be asymmetrical.

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt

Statistical analysis

To empirically assess the risk of bias in the treatment effects in reviews, we will perform stratified analyses across trials according to all the different extracted trial characteristics and derive P-values for interaction between trial characteristics and treatment effect. Within each systematic review, the ES for trial effects according to the different risk of bias assessments will be estimated by using a random effect meta-analysis model. The differences between the pooled estimates will be derived and combined using random effect meta-analysis fully allowing for heterogeneity, to

1
2
3
4
5
6
7
8 1 measure the variability in bias estimates, expressed in τ^2 . A relevant study-level covariate is
9 2 defined as one that decreases the between-study variance (τ^2 , estimated as Tau-squared [T^2]) as a
10 3 consequence of inclusion in the mixed-effects statistical model. All the statistical meta-regression
11 4 analyses will be based on REstricted Maximum Likelihood (REML) (i.e., random-effects) models;³⁶
12 5 models will be developed and analysed using SAS software (version 9.2, by SAS Institute Inc., Cary,
13 6 NC, USA).

20 8 ETHICS AND DISSEMINATION

21
22 9 We believe that the findings of this meta-epidemiological study will have important implications
23 10 for future research strategies and implementation of study conclusions. Meta-analyses and
24 11 randomised controlled trials provide the most reliable basis for treating patients with OA.
25 12 However, even though the influence of bias items is well known and described, authors tend to
26 13 forget that biased trials included in systematic reviews will cause meta-analyses to be biased.³⁷

27 12 Therefore, it is essential that those who conduct systematic reviews be familiar with
28 13 the potential biases within primary studies and how such biases could influence review results and
29 14 the ensuing conclusions. Still, many Cochrane review authors are reluctant or fail to incorporate
30 15 the risk of bias assessment in their analysis and conclusions,³⁸ compromising the trustworthiness
31 16 of results from meta-analysis derived from these reviews. Although the Cochrane Collaboration
32 17 has changed the way it assesses bias in included trials⁵ owing to Ken Schulz's work on bias
33 18 assessment,²³ the Cochrane risk of bias tool in 2008,⁴ AMSTAR (Assessing the methodological
34 19 quality of systematic reviews checklist),³⁹ and the grading of recommendations assessment,
35 20 development and evaluation (GRADE) approach,⁴⁰ meta-analyses might still overestimate the
36 21 effect estimates from biased studies.

37 19 As previously described by Nüesch et al the presence and extent of
38 20 small study effects in OA research might distort the overall evidence from meta-analyses¹⁶. Thus
39 21 the influence of small trials on estimated treatment effects might be considered a novel risk of
40 22 bias domain that needs to be addressed in the future. However, one of the reasons why small
41 23 studies may give different answers from larger studies is that the participants in small studies may
42 24 be more homogeneous than those in larger studies. Thus changes with treatment may be more

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Normal, Indent: First line: 0.91", Line spacing: 1.5 lines, No bullets or numbering, Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers, Pattern: Clear, Tab stops: Not at 0.64" + 1.27" + 1.91" + 2.54" + 3.18" + 3.82" + 4.45" + 5.09" + 5.73" + 6.36" + 7" + 7.63" + 8.27" + 8.91" + 9.54" + 10.18"

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, Font color: Auto

Formatted: Font: (Default) Calibri, 12 pt, Font color: Auto

Formatted: Font: (Default) Calibri, 12 pt, Font color: Auto

1
2
3
4
5
6
7
8 1 similar, and if they are a more severely affected group the potential for gain may be larger. This
9 2 work will facilitate consensus on the need for mandatory sensitivity analyses before making
10 3 conclusions of a meta-analysis if the overall result is not consistent with those of the largest
11 4 trials.¹⁸

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, English (U.K.)

Formatted: Font: (Default) Calibri, 12 pt, Font color: Auto

12 5
13 6
14 7
15 8
16 9
17 10
18 11
19 12
20 13
21 14
22 15
23 16
24 17
25 18
26 19
27 20
28 21
29 22
30 23
31 24
32 25
33 26
34 27
35 28
36 29
37 30
38 31
39 32
40 33
41 34
42 35
43 36
44 37
45 38
46 39
47 40
48 41
49 42
50 43
51 44
52 45
53 46
54 47
55 48
56 49
57 50
58 51
59 52
60 53

After two decades of assessing risk of bias, it is clearly time we examine whether the tool for assessing risk of bias is complete³⁸ What items should be added or removed? Which items have the greatest impact on estimates of effect? This study will examine the evidence in CMSG reviews using patient reported outcomes from OA trials as an example and explore the true implications on effect estimates behind the possible shades of bias. As this study collects no primary data, no additional formal ethical assessment and informed consent are required.

Acknowledgement

We thank the Parker Institute, Frederiksberg Hospital, and The Oak Foundation for creating the possibility and right settings for this research. Additionally, we thank the Cochrane Musculoskeletal Group Editorial based at The University of Ottawa, Centre for Global Health.

Contributors

JBH, RC, CBJ, PT, and HL conceived and designed the study, and JBH, RC, and CBJ contributed to the development of the protocol. All of the authors (JBH, CBJ, IB, PT, EG, JPP, TR, GAW, AM, LM, HL, and RC) assisted in the final protocol and agreed to its final approval before submission.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. This research was funded by The Oak Foundation, which had no role in study design, data collection, data synthesis, data interpretation, writing the report, or the decision to submit the manuscript for publication.

Competing interests

1
2
3
4
5
6
7
8 1 This study had no financial competing interests. The Parker Institute's Musculoskeletal Statistics
9
10 2 Unit is grateful for the financial support received from public and private foundations, companies,
11 3 and private individuals over the years. The Parker Institute is supported by a core grant from the
12 4 Oak Foundation; The Oak Foundation is a group of philanthropic organizations that, since its
13 5 establishment in 1983, has given grants to not-for-profit organisations around the world.
14 6

15
16
17 7 All the authors are involved with different health care initiatives and research (including Cochrane,
18 8 OMERACT, and the GRADE Working Group) that could benefit from wide uptake of this
19 9 publication.
20 10

21 11 REFERENCES

- 22
23
24
25 12 (1) Maxwell L, Santesso N, Tugwell PS, Wells GA, Judd M, Buchbinder R. Method guidelines for
26 13 Cochrane Musculoskeletal Group systematic reviews. *J Rheumatol* 2006; 33(11):2304-2311.
27
28 14 (2) Ghogomu EA, Maxwell LJ, Buchbinder R, Rader T, Pardo PJ, Johnston RV et al. Updated
29 15 method guidelines for cochrane musculoskeletal group systematic reviews and
30 16 metaanalyses. *J Rheumatol* 2014; 41(2):194-205.
31 17 (3) Lundh A, Gotzsche PC. Recommendations by Cochrane Review Groups for assessment of
32 18 the risk of bias in studies. *BMC Med Res Methodol* 2008; 8:22.
33
34 19 (4) Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al. The Cochrane
35 20 Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; 343:d5928.
36
37 21 (5) Turner L, Boutron I, Hrobjartsson A, Altman DG, Moher D. The evolution of assessing bias in
38 22 Cochrane systematic reviews of interventions: celebrating methodological contributions of
39 23 the Cochrane Collaboration. *Syst Rev* 2013; 2:79.
40
41 24 (6) Mulrow CD. The medical review article: state of the science. *Ann Intern Med* 1987;
42 25 106(3):485-488.
43
44 26 (7) Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of
45 27 controlled clinical trials. *BMJ* 2001; 323(7303):42-46.
46
47 28 (8) Sterne JA, Juni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical methods for
48 29 assessing the influence of study characteristics on treatment effects in 'meta-
49 30 epidemiological' research. *Stat Med* 2002; 21(11):1513-1524.
50 31 (9) Gluud LL. Bias in clinical intervention research. *Am J Epidemiol* 2006; 163(6):493-501.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- (10) Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. *Health Technol Assess* 2012; 16(35):1-82.
- (11) Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ* 2008; 336(7644):601-605.
- (12) Nuesch E, Reichenbach S, Trelle S, Rutjes AW, Liewald K, Sterchi R et al. The importance of allocation concealment and patient blinding in osteoarthritis trials: a meta-epidemiologic study. *Arthritis Rheum* 2009; 61(12):1633-1641.
- (13) Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item. *Cochrane Database of Systematic Reviews* 2013.
- (14) Sterne JAC. Why the Cochrane risk of bias tool should not include funding source as a standard item [editorial]. *Cochrane Database of Systematic Reviews* 2013.
- (15) Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P. Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. *Ann Intern Med* 2011; 155(1):39-51.
- (16) Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. *BMJ* 2010; 341:c3515.
- (17) Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. *PLoS One* 2008; 3(8):e3081.
- (18) Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. *BMJ* 2013; 346:f2304.
- (19) Lundh A, Sismondo S, Lexchin J, Busuioic OA, Bero L. Industry sponsorship and research outcome. *Cochrane Database Syst Rev* 2012; 12:MR000033.
- (20) Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Burgi E, Scherer M et al. The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. *BMJ* 2009; 339:b3244.
- (21) Bafeta A, Dechartres A, Trinquart L, Yavchitz A, Boutron I, Ravaud P. Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study. *BMJ* 2012; 344:e813.
- (22) Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I: Medical. *Stat Med* 1989; 8(4):441-454.

- 1
2
3
4
5
6
7
- 8 1 (23) Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of
9 2 methodological quality associated with estimates of treatment effects in controlled trials.
10 3 *JAMA* 1995; 273(5):408-412.
- 11
12 4 (24) Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies
13 5 between large and small randomized trials in meta-analyses. *Ann Intern Med* 2001;
14 6 135(11):982-989.
- 15
16 7 (25) Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al. The PRISMA
17 8 statement for reporting systematic reviews and meta-analyses of studies that evaluate
18 9 healthcare interventions: explanation and elaboration. *BMJ* 2009; 339:b2700.
- 19
20 10 (26) Higgins JPT, Altman D, Sterne JA. Chapter 8: Assessing risk of bias in included studies.
21 11 *Cochrane Handbook for Systematic Reviews of Interventions*. Cochrane Handbook for
22 12 Systematic Reviews of Interventions ed. 2011.
- 23 13 (27) Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in
24 14 randomized drug trials: a reflection of treatment effect or adverse events? *JAMA* 2003;
25 15 290(7):921-928.
- 26
27 16 (28) Juhl C, Lund H, Roos EM, Zhang W, Christensen R. A hierarchy of patient-reported
28 17 outcomes for meta-analysis of knee osteoarthritis trials: empirical evidence from a survey
29 18 of high impact journals. *Arthritis* 2012; 2012:136245.
- 30
31 19 (29) Bellamy N. The WOMAC Knee and Hip Osteoarthritis Indices: development, validation,
32 20 globalization and influence on the development of the AUSCAN Hand Osteoarthritis
33 21 Indices. *Clin Exp Rheumatol* 2005; 23(5 Suppl 39):S148-S153.
- 34
35 22 (30) Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee Injury and Osteoarthritis
36 23 Outcome Score (KOOS)--development of a self-administered outcome measure. *J Orthop*
37 24 *Sports Phys Ther* 1998; 28(2):88-96.
- 38
39 25 (31) Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale
40 26 for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire
41 27 (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS),
42 28 Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant
43 29 Osteoarthritis Pain (ICOAP). *Arthritis Care Res (Hoboken)* 2011; 63 Suppl 11:S240-S252.
- 44 30 (32) Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. *Lancet*
45 31 2005; 365(9463):965-973.
- 46
47 32 (33) Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N et al. OARSI
48 33 recommendations for the management of hip and knee osteoarthritis, Part II: OARSI
49 34 evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage* 2008; 16(2):137-162.
- 50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- (34) Norman GR, Sloan JA, Wyrwich KW. The truly remarkable universality of half a standard deviation: confirmation through another look. *Expert Rev Pharmacoecon Outcomes Res* 2004; 4(5):581-585.
- (35) da Costa BR, Nuesch E, Rutjes AW, Johnston BC, Reichenbach S, Trelle S et al. Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study. *J Clin Epidemiol* 2013; 66(8):847-855.
- (36) Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? *Stat Med* 2002; 21(11):1559-1573.
- (37) Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). *J Clin Epidemiol* 2011; 64(4):407-415.
- (38) Hrobjartsson A, Boutron I, Turner L, Altman DG, Moher D. Assessing risk of bias in randomised clinical trials included in Cochrane Reviews: the why is easy, the how is a challenge. *Cochrane Database Syst Rev* 2013; 4:ED000058.
- (39) Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol* 2007; 7:10.
- (40) Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, onso-Coello P et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336(7650):924-926.



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3,4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5,6,7
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	7
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	7
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	8
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	8
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	9,10,11
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	9,10,11
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	9,10
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	11
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis).	11,12



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	10
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	23
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	No results – this is a protocol
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	No summary of evidence, limitations and conclusion – this is a protocol
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	



PRISMA 2009 Checklist

FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	13

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2